Mainstream

Zurn Elkay raises 2025 guidance with 5%+ core sales growth and $420M–$430M EBITDA outlook amid robust Q2 results

Zurn Elkay raises 2025 guidance with 5%+ core sales growth and $420M–$430M EBITDA outlook amid robust Q2 results

Post ContentzwsRead More

You might also be interested in reading Biggest stock movers Tuesday: MEDP, NXPI, and more.

July 30, 2025
In Mainstream